RFL News and Press, Rafael Holdings Inc. Class B

2026-03-04 05:33:01 ET Alzheimer’s drug development remains fraught with failure, but antioxidant-focused strategies show the most promise compared to anti-amyloid, anti-tau, or anti-inflammatory approaches. Novo Nordisk ( NVO ) may benefit if its GLP-1 receptor a...

2025-12-11 16:03:40 ET More on Rafael Holdings Seeking Alpha’s Quant Rating on Rafael Holdings Financial information for Rafael Holdings Read the full article on Seeking Alpha For further details see: Rafael Holdings GAAP EPS of $0.19, revenue of $...

NEWARK, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the first quarter fiscal year 2026 ended October 31, 2025. “We remain pleased with the progress of our pivotal Phase 3 TransportNPC ™ study evaluating T...

2025-10-29 17:41:02 ET More on Rafael Holdings Seeking Alpha’s Quant Rating on Rafael Holdings Financial information for Rafael Holdings Read the full article on Seeking Alpha For further details see: Rafael Holdings GAAP EPS of -$0.28, revenue of ...

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is continuing at the recommendation of the Data Monitoring Committee (DMC) following their ...

NEWARK, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) sadly announced today the passing of its Lead Independent Director, Stephen Greenberg, and the appointment of Alan Grayson to its Board of Directors. Mr. Grayson will serve on the Compensation...

First data on treatment of NPC1 with Trappsol ® Cyclo™ (hydroxypropyl-beta-cyclodextrin) in this age group over a period of 48 weeks At 48 weeks of the sub-study, 7 of 9 patients 1 showed stabilization or improvement in CGI-S score Data presente...

NEWARK, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) announced today that its subsidiary Cyclo Therapeutics has had two abstracts selected for presentation from its programs evaluating Trappsol ® Cyclo™ for the treatment of Niema...

Phase 3 TransportNPC study to continue based on the independent DMC review of safety and efficacy data at prespecified 48-week interim analysis Data on the investigational candidate Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin), indicates that it is well-tolerated and has...

2025-06-11 07:13:21 ET More on Rafael Holdings Financial information for Rafael Holdings Read the full article on Seeking Alpha For further details see: Rafael Holdings GAAP EPS of -$0.19, revenue of $0.36M